United Therapeutics Stock Debt To Equity

UTHR Stock

USD 371.96 4.60 1.25%

United Therapeutics fundamentals help investors to digest information that contributes to United Therapeutics' financial success or failures. It also enables traders to predict the movement of United Stock. The fundamental analysis module provides a way to measure United Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to United Therapeutics stock.

		Last Reported	Projected for Next Year
	Debt To Equity	0.12	0.17

As of 11/22/2024, Debt To Equity is likely to grow to 0.17.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

United Therapeutics Company Debt To Equity Analysis

United Therapeutics' Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.

D/E

Total Debt

Total Equity

More About Debt To Equity | All Equity Analysis

Current United Therapeutics Debt To Equity

0.18 %

Most of United Therapeutics' fundamental indicators, such as Debt To Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, United Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

United Debt To Equity Driver Correlations

Understanding the fundamental principles of building solid financial models for United Therapeutics is extremely important. It helps to project a fair market value of United Stock properly, considering its historical fundamentals such as Debt To Equity. Since United Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of United Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of United Therapeutics' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Total Liab	Total Current Assets	Good Will	Short Term Investments	Short Term Debt	Intangible Assets	Common Stock	Long Term Debt	Treasury Stock	Property Plant Equipment	Current Deferred Revenue	Net Tangible Assets	Long Term Debt Total	Capital Surpluse	Long Term Investments	Short Long Term Debt	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		1.0	-0.14	0.97	-0.22	0.74	0.89	0.99	0.92	0.95	0.83	0.48	0.47	0.57	-0.69	0.96	0.4	0.98	0.82	0.82	0.93	0.91	0.91	0.89	-0.86
Total Stockholder Equity	1.0		-0.19	0.98	-0.22	0.74	0.85	0.99	0.91	0.95	0.81	0.47	0.43	0.52	-0.68	0.95	0.37	0.99	0.8	0.81	0.92	0.91	0.91	0.89	-0.84
Net Debt	-0.14	-0.19		-0.26	0.12	-0.58	0.12	-0.23	-0.01	0.06	0.13	0.03	-0.28	0.45	0.41	-0.17	0.05	-0.15	0.03	-0.34	0.11	-0.03	0.01	0.01	-0.2
Retained Earnings	0.97	0.98	-0.26		-0.28	0.78	0.83	0.98	0.92	0.89	0.75	0.54	0.46	0.55	-0.8	0.94	0.22	0.97	0.81	0.87	0.87	0.91	0.88	0.86	-0.83
Accounts Payable	-0.22	-0.22	0.12	-0.28		-0.21	-0.2	-0.26	-0.13	-0.2	0.02	0.05	0.06	-0.11	0.28	-0.15	0.14	-0.27	-0.23	-0.36	-0.22	-0.25	-0.28	-0.26	0.32
Net Receivables	0.74	0.74	-0.58	0.78	-0.21		0.63	0.77	0.59	0.54	0.56	0.26	0.65	0.18	-0.76	0.78	0.3	0.69	0.48	0.74	0.55	0.61	0.51	0.5	-0.41
Total Liab	0.89	0.85	0.12	0.83	-0.2	0.63		0.85	0.84	0.83	0.82	0.46	0.6	0.74	-0.68	0.91	0.49	0.82	0.83	0.75	0.84	0.79	0.8	0.77	-0.88
Total Current Assets	0.99	0.99	-0.23	0.98	-0.26	0.77	0.85		0.89	0.94	0.78	0.45	0.47	0.53	-0.73	0.95	0.36	0.98	0.8	0.84	0.88	0.89	0.9	0.9	-0.83
Good Will	0.92	0.91	-0.01	0.92	-0.13	0.59	0.84	0.89		0.88	0.76	0.73	0.47	0.64	-0.74	0.93	0.22	0.89	0.78	0.79	0.84	0.85	0.83	0.8	-0.83
Short Term Investments	0.95	0.95	0.06	0.89	-0.2	0.54	0.83	0.94	0.88		0.81	0.42	0.31	0.6	-0.52	0.88	0.4	0.96	0.78	0.7	0.93	0.87	0.94	0.95	-0.86
Short Term Debt	0.83	0.81	0.13	0.75	0.02	0.56	0.82	0.78	0.76	0.81		0.35	0.47	0.61	-0.46	0.81	0.46	0.79	0.65	0.53	0.85	0.86	0.75	0.73	-0.72
Intangible Assets	0.48	0.47	0.03	0.54	0.05	0.26	0.46	0.45	0.73	0.42	0.35		0.32	0.38	-0.59	0.55	-0.13	0.43	0.45	0.51	0.36	0.48	0.37	0.31	-0.48
Common Stock	0.47	0.43	-0.28	0.46	0.06	0.65	0.6	0.47	0.47	0.31	0.47	0.32		0.35	-0.65	0.64	0.47	0.35	0.48	0.65	0.26	0.3	0.36	0.33	-0.29
Long Term Debt	0.57	0.52	0.45	0.55	-0.11	0.18	0.74	0.53	0.64	0.6	0.61	0.38	0.35		-0.54	0.55	0.14	0.54	0.78	0.55	0.62	0.64	0.63	0.65	-0.78
Treasury Stock	-0.69	-0.68	0.41	-0.8	0.28	-0.76	-0.68	-0.73	-0.74	-0.52	-0.46	-0.59	-0.65	-0.54		-0.75	0.04	-0.65	-0.69	-0.89	-0.48	-0.66	-0.55	-0.54	0.59
Property Plant Equipment	0.96	0.95	-0.17	0.94	-0.15	0.78	0.91	0.95	0.93	0.88	0.81	0.55	0.64	0.55	-0.75		0.46	0.91	0.76	0.82	0.84	0.82	0.82	0.79	-0.79
Current Deferred Revenue	0.4	0.37	0.05	0.22	0.14	0.3	0.49	0.36	0.22	0.4	0.46	-0.13	0.47	0.14	0.04	0.46		0.31	0.24	0.16	0.4	0.15	0.31	0.3	-0.25
Net Tangible Assets	0.98	0.99	-0.15	0.97	-0.27	0.69	0.82	0.98	0.89	0.96	0.79	0.43	0.35	0.54	-0.65	0.91	0.31		0.8	0.79	0.94	0.92	0.93	0.92	-0.85
Long Term Debt Total	0.82	0.8	0.03	0.81	-0.23	0.48	0.83	0.8	0.78	0.78	0.65	0.45	0.48	0.78	-0.69	0.76	0.24	0.8		0.87	0.78	0.81	0.9	0.85	-0.91
Capital Surpluse	0.82	0.81	-0.34	0.87	-0.36	0.74	0.75	0.84	0.79	0.7	0.53	0.51	0.65	0.55	-0.89	0.82	0.16	0.79	0.87		0.65	0.74	0.8	0.76	-0.72
Long Term Investments	0.93	0.92	0.11	0.87	-0.22	0.55	0.84	0.88	0.84	0.93	0.85	0.36	0.26	0.62	-0.48	0.84	0.4	0.94	0.78	0.65		0.9	0.91	0.86	-0.88
Short Long Term Debt	0.91	0.91	-0.03	0.91	-0.25	0.61	0.79	0.89	0.85	0.87	0.86	0.48	0.3	0.64	-0.66	0.82	0.15	0.92	0.81	0.74	0.9		0.87	0.84	-0.85
Net Invested Capital	0.91	0.91	0.01	0.88	-0.28	0.51	0.8	0.9	0.83	0.94	0.75	0.37	0.36	0.63	-0.55	0.82	0.31	0.93	0.9	0.8	0.91	0.87		0.97	-0.89
Net Working Capital	0.89	0.89	0.01	0.86	-0.26	0.5	0.77	0.9	0.8	0.95	0.73	0.31	0.33	0.65	-0.54	0.79	0.3	0.92	0.85	0.76	0.86	0.84	0.97		-0.84
Capital Stock	-0.86	-0.84	-0.2	-0.83	0.32	-0.41	-0.88	-0.83	-0.83	-0.86	-0.72	-0.48	-0.29	-0.78	0.59	-0.79	-0.25	-0.85	-0.91	-0.72	-0.88	-0.85	-0.89	-0.84

Click cells to compare fundamentals

United Debt To Equity Historical Pattern

Today, most investors in United Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various United Therapeutics' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's debt to equity growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of United Therapeutics debt to equity as a starting point in their analysis.

United Therapeutics Debt To Equity

Timeline

High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.

Competition

Predict United Therapeutics

Debt To Equity Over Time

United Total Stockholder Equity

Total Stockholder Equity

6.28 Billion

At this time, United Therapeutics' Total Stockholder Equity is relatively stable compared to the past year.

According to the company disclosure, United Therapeutics has a Debt To Equity of 0.185%. This is 99.65% lower than that of the Biotechnology sector and 99.04% lower than that of the Health Care industry. The debt to equity for all United States stocks is 99.62% higher than that of the company.

United Debt To Equity Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses United Therapeutics' direct or indirect competition against its Debt To Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of United Therapeutics could also be used in its relative valuation, which is a method of valuing United Therapeutics by comparing valuation metrics of similar companies.

United Therapeutics is currently under evaluation in debt to equity category among its peers.

United Therapeutics ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, United Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to United Therapeutics' managers, analysts, and investors.

Environmental

Governance

Social

United Fundamentals

	Return On Equity	0.19
	Return On Asset	0.12
	Profit Margin	0.40 %
	Operating Margin	0.55 %
	Current Valuation	13.18 B
	Shares Outstanding	44.64 M
	Shares Owned By Insiders	1.84 %
	Shares Owned By Institutions	98.16 %
	Number Of Shares Shorted	2.3 M
	Price To Earning	23.49 X
	Price To Book	2.64 X
	Price To Sales	5.90 X
	Revenue	2.33 B
	Gross Profit	1.78 B
	EBITDA	1.39 B
	Net Income	984.8 M
	Cash And Equivalents	2.26 B
	Cash Per Share	49.55 X
	Total Debt	700 M
	Debt To Equity	0.18 %
	Current Ratio	8.10 X
	Book Value Per Share	136.74 X
	Cash Flow From Operations	978 M
	Short Ratio	7.51 X
	Earnings Per Share	22.76 X
	Price To Earnings To Growth	1.56 X
	Target Price	382.29
	Number Of Employees	1.17 K
	Beta	0.56
	Market Capitalization	16.27 B
	Total Asset	7.17 B
	Retained Earnings	6.03 B
	Working Capital	2.75 B
	Current Asset	1.28 B
	Current Liabilities	440.82 M
	Net Asset	7.17 B

About United Therapeutics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze United Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of United Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of United Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Pair Trading with United Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if United Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in United Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving together with United Stock

0.66

EWTX

Edgewise Therapeutics

Pair Corr

Moving against United Stock

0.74	PALI	Palisade Bio	Pair Corr
0.66	MRK	Merck Company Fiscal Year End 6th of February 2025	Pair Corr
0.64	JNJ	Johnson Johnson Fiscal Year End 28th of January 2025	Pair Corr
0.59	INZY	Inozyme Pharma	Pair Corr
0.54	PFE	Pfizer Inc Fiscal Year End 4th of February 2025	Pair Corr

The ability to find closely correlated positions to United Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace United Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back United Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling United Therapeutics to buy it.

The correlation of United Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as United Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if United Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for United Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Additional Tools for United Stock Analysis

When running United Therapeutics' price analysis, check to measure United Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy United Therapeutics is operating at the current time. Most of United Therapeutics' value examination focuses on studying past and present price action to predict the probability of United Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move United Therapeutics' price. Additionally, you may evaluate how the addition of United Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC